北欧资本和Permira拟以19亿丹麦克朗的价格,即21%的溢价收购巴伐利亚北欧. Nordic Capital and Permira propose to buy Bavarian Nordic for DKK 19 billion, a 21% premium.

一个由北欧首都和佩尔米拉领导的财团提议以190亿丹麦克朗的价格购买丹麦北欧巴伐利亚生物制药公司,每股提供233丹麦克朗,相当于21%的溢价。 A consortium led by Nordic Capital and Permira has proposed to buy Danish biopharmaceutical company Bavarian Nordic for about DKK 19 billion, offering DKK 233 per share, a 21% premium. 巴伐利亚北欧的董事会和行政人员 同意出价他们的股份。 Bavarian Nordic's board and executives agree to tender their shares. 如果成功,这笔交易将使该公司从哥本哈根的Nasdaq公司除名。 If successful, the deal would delist the company from Nasdaq Copenhagen. 预计到2025年底结束的交易须得到监管批准和其他条件。 The transaction, expected to close by end of 2025, is subject to regulatory approvals and other conditions.